Sanfilippo syndrome type A is a subtype of mucopolysaccharidosis type III, an inherited lysosomal storage disorder that primarily affects the central nervous system. It causes progressive cognitive, behavioral, and physical decline over time.
Ultragenyx Pharmaceutical confronts multiple shareholder class action lawsuits over Phase III trial disclosures while reporting positive UX111 gene therapy data and implementing a 10% workforce reduction.
Ultragenyx Pharmaceutical announced positive long-term clinical data for UX111 gene therapy for Sanfilippo syndrome Type A, with up to 8.5 years of follow-up showing sustained biomarker reductions and functional improvements. The company resubmitted its BLA to the FDA in January 2026.
Ultragenyx Pharmaceutical received an Incomplete Response Letter from the FDA for its UX111 gene therapy resubmission for Sanfilippo syndrome type A, requesting additional documentation. The company announced a 10% workforce reduction and expects profitability by 2027.
Ultragenyx will lay off 130 employees as part of restructuring aimed at profitability by 2027. The FDA rejected the company's gene therapy application for Sanfilippo syndrome due to manufacturing concerns.
Ultragenyx reported Q4 2025 revenues of $207 million, up 25% year-over-year, while announcing a 10% workforce reduction and resubmission of its UX111 gene therapy application following positive long-term clinical data.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT06567769 |
Phase 1 Study of GC1130A in Patients With Sanfilippo Syndrome Type A (MPS IIIA) |
RECRUITING | PHASE1 |
| NCT01873911 |
Neurobehavioral Phenotypes in MPS III |
COMPLETED | |
| NCT01047306 |
A Study of Patients With Sanfilippo Syndrome Type A (MPS IIIA) |
COMPLETED |
